These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 34070277)

  • 1. Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.
    Scarpini S; Morigi F; Betti L; Dondi A; Biagi C; Lanari M
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34070277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the current status of cytomegalovirus vaccines.
    Sung H; Schleiss MR
    Expert Rev Vaccines; 2010 Nov; 9(11):1303-14. PubMed ID: 21087108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection.
    Nelson CS; Herold BC; Permar SR
    NPJ Vaccines; 2018; 3():38. PubMed ID: 30275984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of congenital asymptomatic cytomegalovirus infection on development of infants].
    Shan RB; Wang XL; Fu P
    Zhonghua Er Ke Za Zhi; 2008 Sep; 46(9):658-61. PubMed ID: 19099851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Live Olfactory Mouse Cytomegalovirus Vaccine, Attenuated for Systemic Spread, Protects against Superinfection.
    Farrell HE; Bruce K; Stevenson PG
    J Virol; 2021 Oct; 95(21):e0126421. PubMed ID: 34431701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
    Gerna G; Lilleri D
    New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?
    Schleiss MR
    Future Virol; 2013 Dec; 8(12):1161-1182. PubMed ID: 24523827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.
    Hu X; Wang HY; Otero CE; Jenks JA; Permar SR
    Annu Rev Virol; 2022 Sep; 9(1):491-520. PubMed ID: 35704747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current Approaches in the Diagnosis and Management of Congenital Cytomegalovirus Infections and the Situation in Turkey].
    Şahiner F
    Mikrobiyol Bul; 2020 Jan; 54(1):171-190. PubMed ID: 32050888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus vaccine development.
    Schleiss MR
    Curr Top Microbiol Immunol; 2008; 325():361-82. PubMed ID: 18637516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting viral natural history for vaccine development.
    Barry PA
    Med Microbiol Immunol; 2015 Jun; 204(3):255-62. PubMed ID: 25794555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of the Viral Pentamer Complex in a Vaccine Design Greatly Improves Protection against Congenital Cytomegalovirus in the Guinea Pig Model.
    Choi KY; El-Hamdi NS; McGregor A
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31484753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections.
    Permar SR; Schleiss MR; Plotkin SA
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.
    Perotti M; Perez L
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31905677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
    Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.
    Plachter B
    Med Microbiol Immunol; 2016 Dec; 205(6):537-547. PubMed ID: 27519596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital Human Cytomegalovirus Infection: A Narrative Review of Maternal Immune Response and Diagnosis in View of the Development of a Vaccine and Prevention of Primary and Non-Primary Infections in Pregnancy.
    Gerna G; Fornara C; Furione M; Lilleri D
    Microorganisms; 2021 Aug; 9(8):. PubMed ID: 34442828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel vaccines against human cytomegalovirus.
    Cui X; Snapper CM
    Hum Vaccin Immunother; 2019; 15(11):2673-2683. PubMed ID: 31017831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.